

CFA of Application No. 09/455,543
Attorney Docket No. 045112-0045

24. The composition of claim 22, wherein thymol is selected on a basis of therapeutic treatment for soft tissue cancer.

25. A composition for the treatment of cancerous medical conditions, said composition comprising a serine/threonine protein phosphatase inhibitor and a compound selected from a group consisting of thymol and eugenol.

26. The composition of claim 25, wherein the serine/threonine protein phosphatase inhibitor is okadaic acid.

27. The composition of claim 26, wherein eugenol is selected on a basis of therapeutic treatment for soft tissue cancer.

28. The composition of claim 26, wherein thymol is selected on a basis of therapeutic treatment for soft tissue cancer.

REMARKS

Claims 1, 5-14, 16 and 17- 28 are pending in the application. Claim 15 has been previously withdrawn from consideration as being directed to non-elected subject matter and is herein canceled without prejudice to, or disclaimer of, the subject matter it contains. Applicants respectfully reserve the right to file continuation applications. Claims 1, 5-14, and 16 are amended and new Claims 17-28 are added in an effort to encompass infringing subject matter. No new subject matter is added into the application.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned, "Version With Markings To Show Changes Made."

CONCLUSION:

If any issues remain outstanding or if an Examiner's amendment could be made to advance prosecution, then Applicants respectfully invite the Examiner to contact the undersigned representative at the telephone number listed below.


CPA of Application No. 09/455,543
Attorney Docket No. 045112-0045

Please grant any extensions of time deemed necessary for entry of this communication.
Please charge any deficient fees, including Notice of Appeal fees, or credit any overpayment of fees, to Deposit Account No. 5000417.

Respectfully submitted,

McDermott, Will & Emery

By:


Willem F. Gadiano
Registration No. 37,136

DATE: October 10, 2002

MCDERMOTT, WILL & EMERY
600 13th Street, N.W.
Washington, D.C. 20005-3096
(202) 756-8351 (direct)
(202) 756-8087 (fax)

10/10/02 THU 15:07 FAX

010

CPA of Application No. 09/455,543
Attorney Docket No. 045112-0045

5. (Amended) The [pharmaceutical] composition of claim 1, wherein the soft tissue cancer is breast cancer.

6. (Amended) The [pharmaceutical] composition of claim 1, wherein [the compound is]eugenol is selected on a basis of therapeutic treatment for soft tissue cancer.

7. (Amended) The [pharmaceutical] composition of claim 1, wherein [the compound is]thymol is selected on a basis of therapeutic treatment for soft tissue cancer.

8. (Amended) The [pharmaceutical] composition of claim 1, wherein [the compound is]isoeugenol is selected on a basis of therapeutic treatment for soft tissue cancer.

9. (Amended) The [pharmaceutical] composition of claim 1, wherein [the compound is]benzyl alcohol is selected on a basis of therapeutic treatment for soft tissue cancer.

10. (Amended) The [pharmaceutical] composition of claim 1, wherein [the compound is]carvacrol is selected on a basis of therapeutic treatment for soft tissue cancer.

11. (Amended) The [pharmaceutical] composition of claim 1, wherein [the compound is]cinnamic alcohol is selected on a basis of therapeutic treatment for soft tissue cancer.

12. (Amended) The [pharmaceutical] composition of claim 1, wherein [the compound is]cinnamic aldehyde is selected on a basis of therapeutic treatment for soft tissue cancer.

13. (Amended) The [pharmaceutical] composition of claim 1, wherein [the compound is]citronellal is selected on a basis of therapeutic treatment for soft tissue cancer.

14. (Amended) The [pharmaceutical] composition of claim 1, wherein [the compound is]trans-anethole is selected on a basis of therapeutic treatment for soft tissue cancer.

15. (Canceled)

CPA of Application No. 09/455,543
Attorney Docket No. 045112-0045

16. (Amended) The [pharmaceutical] composition of claim 1, wherein [the compound is] α -terpineol is selected on a basis of therapeutic treatment for soft tissue cancer.

New Claims 17-28 are added as follow.

17. [NEW] A composition for the treatment of cancerous medical conditions, said composition comprising a cAMP inducer and a compound selected from a group consisting of α -terpineol, benzyl alcohol, carvacrol, eugenol, isocugenol, cinnamic aldehyde, thyme oil, thymol, trans-anethole, said composition having a pharmaceutically effective amount of the compound selected on a basis of a therapeutic treatment for soft tissue cancer.

18. [NEW] The composition of claim 17, wherein the cAMP inducer is forskolin.

19. [NEW] The composition of claim 18, wherein eugenol is selected on a basis of therapeutic treatment for soft tissue cancer.

20. [NEW] The composition of claim 18, wherein cinnamic aldehyde is selected on a basis of therapeutic treatment for soft tissue cancer.

21. [NEW] A composition for the treatment of cancerous medical conditions, said composition comprising a c-Src kinase inhibitor and a compound selected from a group consisting of thymol and eugenol, said composition having a pharmaceutically effective amount of the compound selected on a basis of a therapeutic treatment for soft tissue cancer.

22. [NEW] The composition of claim 21, wherein geldanamycin is the c-Src kinase inhibitor.

23. [NEW] The composition of claim 22, wherein eugenol is selected on a basis of therapeutic treatment for soft tissue cancer.

CPA of Application No. 09/455,543
Attorney Docket No. 045112-0045

24. [NEW] The composition of claim 22, wherein thymol is selected on a basis of therapeutic treatment for soft tissue cancer.

25. [NEW] A composition for the treatment of cancerous medical conditions, said composition comprising a serine/threonine protein phosphatase inhibitor and a compound selected from a group consisting of thymol and eugenol.

26. [NEW] The composition of claim 25, wherein the serine/threonine protein phosphatase inhibitor is okadaic acid.

27. [NEW] The composition of claim 26, wherein eugenol is selected on a basis of therapeutic treatment for soft tissue cancer.

28. [NEW] The composition of claim 26, wherein thymol is selected on a basis of therapeutic treatment for soft tissue cancer.

ATTACHMENT
Version With Markings To Show Changes Made

IN THE CLAIMS

Claim 15 is canceled, without prejudice to, or disclaimer of, the subject matter they contain.

Claims 1, 5-14 and 16 are amended as follow.

1. (Twice Amended) A [pharmaceutical]composition for the treatment of cancer, said composition comprising, in admixture with an acceptable carrier, [in soft tissue cancer in mammals comprising a pharmaceutically effective amount of] at least one compound selected from a[the] group consisting of [aldehyde C16 (pure), amyl cinnamic aldehyde, amyl salicylate, anisic aldehyde,]benzyl alcohol, [benzyl acetate,]cinnamic aldehyde, cinnamaldehyde, cinnamic alcohol, α -terpineol, carvacrol, [carveol, citral,]citronellal, [citronellol, p-cymene, diethyl phthalate, dimethyl salicylate, dipropylene glycol, eucalyptol (cineole),]eugenol, iso-eugenol, [galaxolide, geraniol, guaiacol, ionone, d-limonene, menthol, methyl anthranilate, methyl ionone, methyl salicylate, α -phellandrene, pennyroyal oil perillaldehyde, 1- or 2-phenyl ethyl alcohol, 1- or 2-phenyl ethyl propionate, piperonal, piperonyl acetate, piperonyl alcohol, D-pulegone, terpinen-4-ol, terpinyl acetate, 4-*tert* butylcyclohexyl acetate,]thyme oil, thymol, [metabolites of]trans-anethole[, vanillin, and ethyl vanillin]and at least one signal transduction modulator selected from a[the] group consisting of cyclic adenosine monophosphate (cAMP), cAMP-dependent protein kinase, tyrosine kinase, calcium phospholipid-dependent protein kinase (PKC), mitogen activated protein kinase family members, calcium-calmodulin-dependent protein kinase, and growth factor receptor inhibitors, said composition having a pharmaceutically effective amount of the compounds selected on a basis of a therapeutic treatment for soft tissue cancer[, wherein the composition has antiestrogenic activity].

2. (Canceled)
3. (Canceled)
4. (Canceled)